Phase 3 Trial of SRG-514 in Triple Negative Breast Cancer Undergoing Surgery
A Phase 3 trial is underway to evaluate SRG-514, an intraoperative treatment for patients with triple negative breast cancer.
Phase III
triple negative breast cancer treatment protocols
Status
Negative
Sponsor
SURGE Therapeutics
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase 3 trial of SRG-514 could significantly influence treatment standards for triple negative breast cancer, a challenging oncology area. Its success may reshape surgical management practices and competitive dynamics in the oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding efficacy and safety compared to standard-of-care.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.